# DaVita Venture Group

> DaVita Venture Group is a VC fund in Denver backing Health Care, Medical and Biotechnology. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Denver, United States
- Total investments: 13
- Last investment: Jul 2026
- Lead investor: 23%
- Last updated: Aug 2026
- Website: https://www.davitaventuregroup.com/

DaVita Venture Group is a VC fund in Denver focused on Health Care and Medical. DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease. Together, we believe we can transform the future of patient care for the better.DaVita Venture Group is part of DaVita Inc., a Fortune 500® health care provider focused on transforming care delivery topatients around the globe. We aim to invest in, develop and launch products, solutions and businesses that improve care for patients with kidney disease and related conditions.Bringing patient-centered chronic care to scale requires reimagining health care as it exists today. As a result, DaVita Venture Group targets companies and products that support our vision across a few key areas of focus:Digital Health: Digitally enabled products and services that leverage technology, data and connectivity to improve care delivery.Pharmaceuticals and Medical Devices: Products that will improve clinical outcomes and patient experience while reducing costs for the health care system.Care Delivery Models: Advancements that expand access to care and improve clinical outcomes by accelerating the adoption of home treatments and value-based care.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 62% |
| Medical | 5 | 38% |
| Biotechnology | 3 | 23% |
| Wellness | 2 | 15% |
| Therapeutics | 2 | 15% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 31% |
| Series B | 4 | 31% |
| Seed | 2 | 15% |
| Series D | 1 | 8% |
| Venture - Series Unknown | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 54% |
| Switzerland | 1 | 8% |
| United Kingdom | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xeltis | A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $23.3M | Venture - Series Unknown | Jul 28, 2026 |  |
| R1 Therapeutics | R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $77.5M | Series A | Mar 17, 2026 |  |
| Greater Good Health | We aim to extend the reach of health plans, services offered through Medicare for seniors, and provider organizations in the communities they serve by enabling sophisticated value-based care programs that focus on quality improvement, and by creating access to high-quality senior primary care in markets that are struggling with physician shortages. | $20.5M | Series B | Dec 29, 2025 |  |
| Pathalys Pharma | Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. | $105M | Series B | Aug 20, 2024 |  |
| Xeltis | A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $13.7M | Series D | Aug 14, 2023 |  |
| Dock Health | Dock Health is a HIPAA compliant task management and collaboration platform designed for healthcare. The company is focused on solving some of the most pressing issues in healthcare by making communication and collaboration easier through thoughtful design and simplicity. Dock is on a mission to solve the workflow challenges and inefficiencies forclinicians and their teams. Dock Health hopes to improve patient care by giving medical teams a reliable and secure system to ensure the work gets done.Founded in 2016, Dock Health is headquartered in Boston, Massachusetts. | $5M | Seed | May 24, 2023 |  |
| Xeltis | A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $34.1M | Series D | Feb 21, 2023 |  |
| Pathalys Pharma | Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. | $150M | Series A | Jan 18, 2023 |  |
| Pathalys Pharma | Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. | $11M | Seed | Jun 22, 2021 |  |
| Heartbeat Health | Heartbeat Health is a healthcare technology company that delivers virtual-first cardiovascular disease prevention and management. Through its data-powered platform and clinical services, the company helps patients and at-risk organizations benefit from higher-value care by reducing cardiovascular risk and the likelihood of future adverse events. Itoffers tools and resources critical to supporting digital care by virtually connect patients with doctors securely and helps in sharing information in real-time, and collaborate on treatment and diet consultation, and helps patients to keep track of their heart health and be in touch with a cardiologist. | $20M | Series B | May 10, 2021 |  |

10 of 13 investments shown.

## Co-investors
- [Catalys Pacific](https://shizune.co/investors/profile/catalys-pacific) — VC Fund, 4 deals together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 3 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 3 deals together
- [.406 Ventures](https://shizune.co/investors/profile/406-ventures) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Invest-NL](https://shizune.co/investors/profile/invest-nl) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does DaVita Venture Group invest in?

DaVita Venture Group invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did DaVita Venture Group last invest?

The most recent investment recorded for DaVita Venture Group closed in Jul 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co